Health Logic Interactive Inc. announced its second update to its digital diagnostic device MATLOC 1. MATLOC 1 is the Company's proprietary diagnostic platform technology in development for the testing of different biomarkers, with a current focus on the urine-based biomarkers albumin and creatinine for chronic kidney disease (CKD) screening and eventual diagnosis. Current development activities continue to focus on MATLOC 1 and the Company's accompanying lab-on-chip products. MATLOC 1 is wrapping up its first phase of development, which included the building and testing of a fluid handling apparatus, the completion of a user interaction study, and initial design concepts that will lead to a functional prototype for the second phase of development. The prototype to be developed in Phase 2 is expected to be used in the Company's clinical trials, which are anticipated to commence in first quarter of 2022. The Company's lab-on-chip technology is focused on achieving better detection sensitivity and shorter test times for the urine creatinine chip (uC-Chip). Recent developments in the Company's lab-on-chip technology have shown promising results in achieving these goals and advances the Company closer to an integrated urine albumin creatinine chip (uACR-Chip). The Company also continues to advance its work done on its blood based eGFR detection chip (eGFR-Chip), especially on its signal optimization to provide a more complete proof-of-concept eGFR-Chip. The Company's United States Food and Drug Administration pre-submission meeting that was anticipated to occur in September has been postponed by the FDA due to the FDA's necessity to allocate resources to COVID-19 related activities. It is expected that the Pre-Submission Meeting will be delayed until early in the 2022 calendar year. The Company will continue with its current plan to complete the product development of MATLOC 1, conduct analytical validation of the product, and evaluate the product's status with the Company's FDA regulatory consultants in January 2022. At that time, Health Logic expects to either submit a pre-submission plan to the FDA or move forward with a formal FDA 510(k) application.